A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT06413498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Study identification
- NCT ID
- NCT06413498
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 452 participants
Conditions and interventions
Conditions
Interventions
- Anitocabtagene Autoleucel Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Pomalidomide Drug
- Bortezomib Drug
- Dexamethasone Drug
- Daratumumab Drug
- Carfilzomib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 23, 2024 (Actual)
- Primary completion
- Jul 2028 (Estimated)
- Completion
- Jul 2031 (Estimated)
- Last update posted
- Jul 29, 2026
2024 – 2031
United States locations
- U.S. sites
- 46
- U.S. states
- 25
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic Hospital | Gilbert | Arizona | 85234 | — |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| UC San Diego Moores Cancer Center | San Diego | California | 92037 | — |
| UCLA Hematology/Oncology (Bowyer Infusion Clinic) | Santa Monica | California | 90404 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Sylvester Comprehensive Cancer Center | Coral Gables | Florida | 33146 | — |
| Mayo Clinic | Jacksonville | Florida | 32256 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta | Newnan | Georgia | 30265 | — |
| St. Luke's Cancer Institute | Boise | Idaho | 83712 | — |
| University of Illinois Hospital and Health Sciences System | Chicago | Illinois | 60612 | — |
| IU Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Ochsner Clinical Foundation | New Orleans | Louisiana | 70121 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Corewell Health - Lemmen-Holton Cancer Pavilion | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy | Omaha | Nebraska | 68130 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| New Mexico Cancer Research Alliance | Albuquerque | New Mexico | 87102 | — |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| Weill Cornell Medicine - New York Presbyterian Hosptial | New York | New York | 10021 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Novant Health Cancer Institute Hematology- Forsyth | Winston-Salem | North Carolina | 27103 | — |
| University of Cincinnati Cancer Center | Cincinnati | Ohio | 45219 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38104 | — |
| Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research | Nashville | Tennessee | 37203 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| St. David's South Austin Medical Center | Austin | Texas | 78704 | — |
| Houston Methodist Hospital Cancer Center | Houston | Texas | 77030 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute, University of Utah | Salt Lake City | Utah | 84112 | — |
| LDS Hospital | Salt Lake City | Utah | 84143 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06413498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2026 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06413498 live on ClinicalTrials.gov.